Fig. 1.
BCR-ABL/GAPDH ratios in serial analysis of imatinib-treated relapsed CML transplantation patients.
The BCR-ABL/GAPDH ratio is expressed as a percentage following RQ-PCR analysis of reverse transcribed cDNA samples. Both patients 1 and 3 were 100% Ph-positive at time 0, whereas patient 2 exhibited 40% Ph-positivity. Both patients 1 and 2 achieved complete BCR-ABL negativity, whereas patient 3 exhibited extremely low BCR-ABL/GAPDH ratio (1 × 10−5) at 14 months.
